We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer (MEDOBREC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00496795
Recruitment Status : Active, not recruiting
First Posted : July 4, 2007
Last Update Posted : October 30, 2017
Sponsor:
Collaborator:
Haukeland University Hospital
Information provided by (Responsible Party):
Per Eystein Lonning, University of Bergen

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : May 2016
  Estimated Study Completion Date : May 2026